By Nigam Arora
Fortunes may be made in legal cannabis over the coming years. As a result, bullish sentiment is building on cannabis stocks both for recreational and medicinal uses.
Adding to the bullish sentiment is the first-ever cannabis-based medicine to get a favorable recommendation from an advisory panel to the U.S. Food and Drug Administration. This is a big win for cannabis.
The drug, a syrup called Epidiolex, is from GW Pharmaceuticals GWPH, +1.97% GW2A, +0.00% to treat childhood epilepsy. The medicine doesn’t have any psychoactive effects.
Read more at MarketWatch